Products
Susoctocog alfa is commercially available as a powder and solvent for solution for injection (Obizur). It was approved in the United States in 2014, in the EU in 2015, and in many countries in 2016.
Structure and properties
Susoctocog alfa is a recombinant derivative of porcine blood clotting factor VIII lacking the B domain. The B domain has been replaced by a linker of 24 amino acids. It is a glycoprotein with a molecular weight of approximately 170 kDa. Susoctocog alfa is produced by biotechnological methods.
Effects
Susoctocog alfa (ATC B02BD14) replaces the missing blood clotting factor VIII, thereby enabling blood clotting.
Indications
For the treatment of bleeding episodes in patients with acquired hemophilia caused by antibodies to factor VIII.
Dosage
According to the SmPC. The drug is injected intravenously.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Drug-drug interactions are not known.
Adverse effects
The most common possible adverse effects include the formation of antibodies to susoctocog alfa.
